德維特 DVA 深 滬
等待開盤 12-18 09:30:00 美东时间
118.42
+0.480
+0.41%
華盛通- 最 高120.08
- 今 開117.78
- 成交量 58.82万股
- 最 低 117.50
- 昨 收 117.94
- 總市值 89.50亿
- 52周最高 179.60
- 市盈率 靜 11.04
- 換手率 0.78%
- 52周最低 113.97
- 委 比 -55.04%
- 總股本 7557.70万
- 歷史最高 179.60
- 量 比 0.63
- 振 幅 2.19%
- 歷史最低 43.40
- 每 手 1
- 風險率 13.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Most shorted S&P 500 stocks in November
Charter Communications (CHTR) emerged as the most shorted S&P 500 (SP500) stock as a percentage of float in November, followed by Moderna (MRNA) and Super Micro Computer (SMCI). Charter Communications...
12-11 22:35
DaVita Names New Leaders to Accelerate Care Transformation
Appointments of Chief People Officer and Chief Strategy Officer underscore commitment to innovation and people-first approach DENVER, Dec. 11, 2025 /PRNewswire/ -- DaVita, a leading provider...
12-11 21:00
DaVita Amends Credit Agreement for $3.5 Billion Loan
The latest update is out from DaVita ( ($DVA) ). On November 24, 2025, DaVita I...
11-26 06:25
Warren Buffett Initiates Alphabet Position, Trims Apple In Q3 — Here Are Berkshire's Moves
Warren Buffett's Berkshire Hathaway took a new stake in a member of the Magnificent Seven, while lowering its stake in Apple in the third quarter.
11-15 05:36
DaVita Inc. to Participate in Fireside Chat with Wolfe Research
DENVER, Nov. 14, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat at the Wolfe Research Healt...
11-15 05:16
Goldman says healthcare is ripe for stock picking; here's some they like
The healthcare sector’s slump had created opportunities for stock-pickers rather than broad sector gains, Goldman Sachs strategist David Kostin said. Healthcare (XLV) has lagged the S&P 500 (SPY) (IVV...
11-11 00:19
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Akebia Therapeutics三季度净收入14.3百万美元，Vafseo销量增长显著。与DaVita合作试点预计年底完成，覆盖27.5万患者。临床数据显示Vadadustat优于ESA，治疗肾性贫血更具优势。计划11月10日召开电话会议。
11-10 12:00
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
TD Cowen Maintains Hold on DaVita, Lowers Price Target to $133
TD Cowen analyst Ryan Langston maintains DaVita (NYSE:DVA) with a Hold and lowers the price target from $154 to $133.
11-04 00:25
电话会总结 ｜ DaVita(DVA)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据DaVita 2025年第三季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **第三季度核心财务指标：** - 调整后营业收入：5.17亿美元，符合内部预期 - 调整后每股收益：2.51美元 - 自由现金流：6.04亿美元 - 美国透析治疗量：同比下降约1.5%，主要受严重流感季节高死亡率、飓风海伦娜和网络安全事件影响 - 单次治疗收入(RPT)：环比第二季度增长约6美元，主要由费率上调和磷酸盐结合剂收入增长推动 - 单次治疗患者护理成本：环比增长约5美元，主要因工资费用上升和磷酸盐结合剂配药量增加 ## 2. 财务指标变化 **
10-30 12:02
